Astrazeneca PLC (AZN) Given “Buy” Rating at Deutsche Bank AG
Several other equities research analysts also recently commented on the company. Shore Capital reiterated a hold rating on shares of Astrazeneca PLC in a report on Wednesday, July 27th. Bank of America Corp. restated a buy rating and set a $36.65 price objective on shares of Astrazeneca PLC in a research note on Monday, July 18th. Citigroup Inc. restated a buy rating on shares of Astrazeneca PLC in a research note on Friday, September 23rd. Berenberg Bank restated a buy rating on shares of Astrazeneca PLC in a research note on Sunday, September 11th. Finally, Beaufort Securities restated a hold rating on shares of Astrazeneca PLC in a research note on Friday, August 26th. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have given a buy rating and two have given a strong buy rating to the stock. Astrazeneca PLC has a consensus rating of Buy and an average price target of $37.56.
Astrazeneca PLC (NYSE:AZN) traded down 1.56% during midday trading on Monday, hitting $31.56. The stock had a trading volume of 624,535 shares. Astrazeneca PLC has a one year low of $26.97 and a one year high of $35.04. The stock has a 50-day moving average price of $33.19 and a 200 day moving average price of $30.86. The firm has a market cap of $79.85 billion, a PE ratio of 36.07 and a beta of 0.75.
Astrazeneca PLC (NYSE:AZN) last announced its earnings results on Thursday, July 28th. The company reported $0.83 EPS for the quarter, beating the consensus estimate of $0.76 by $0.07. The business had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.56 billion. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The company’s revenue was down 4.0% on a year-over-year basis. During the same period last year, the business posted $1.21 EPS. On average, analysts predict that Astrazeneca PLC will post $2.97 earnings per share for the current year.
The business also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were given a $0.44 dividend. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio is currently 78.29%.
Several hedge funds have recently made changes to their positions in AZN. Forester Capital Management LTD boosted its stake in shares of Astrazeneca PLC by 68.4% in the first quarter. Forester Capital Management LTD now owns 3,200 shares of the company’s stock worth $109,000 after buying an additional 1,300 shares in the last quarter. First Interstate Bank boosted its stake in shares of Astrazeneca PLC by 233.3% in the second quarter. First Interstate Bank now owns 3,900 shares of the company’s stock worth $118,000 after buying an additional 2,730 shares in the last quarter. Synovus Financial Corp boosted its stake in shares of Astrazeneca PLC by 29.7% in the second quarter. Synovus Financial Corp now owns 4,372 shares of the company’s stock worth $132,000 after buying an additional 1,000 shares in the last quarter. Fifth Third Bancorp boosted its stake in shares of Astrazeneca PLC by 2.3% in the second quarter. Fifth Third Bancorp now owns 4,631 shares of the company’s stock worth $140,000 after buying an additional 103 shares in the last quarter. Finally, Integrated Investment Consultants LLC boosted its stake in shares of Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock worth $144,000 after buying an additional 275 shares in the last quarter. 11.39% of the stock is owned by institutional investors.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related stocks with our FREE daily email newsletter.